Open AccessCost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer
Author(s) -
Matthew J. Ehrhardt,
Zachary J. Ward,
Qi Liu,
Aeysha Chaudhry,
Anju Nohria,
William L. Border,
Joy M. Fulbright,
Daniel A. Mulrooney,
Kevin C. Oeffinger,
Paul C. Nathan,
Wendy Leisenring,
Louis S. Constine,
Todd M. Gibson,
Eric J. Chow,
Rebecca M. Howell,
Leslie L. Robison,
Gregory T. Armstrong,
Melissa M. Hudson,
Lisa Diller,
Yutaka Yasui,
Saro H. Armenian,
Jennifer M. Yeh
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.00418
Subject(s) - medicine , guideline , cohort , quality adjusted life year , anthracycline , cost effectiveness , cancer , cohort study , confidence interval , pediatrics , breast cancer , pathology , risk analysis (engineering)
Survivors of childhood cancer treated with anthracyclines and/or chest-directed radiation are at increased risk for heart failure (HF). The International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) recommends risk-based screening echocardiograms, but evidence supporting its frequency and cost-effectiveness is limited.